Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

NCT00001041 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
Pregnancy

Interventions

BIOLOGICAL: rgp120/HIV-1MN

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)